Tellgen Corp (300642) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.024x

Based on the latest financial reports, Tellgen Corp (300642) has a cash flow conversion efficiency ratio of 0.024x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥36.19 Million ≈ $5.30 Million USD) by net assets (CN¥1.53 Billion ≈ $223.58 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Tellgen Corp (300642) liquidity interval to measure how many days the company can operate on defensive assets alone.

Tellgen Corp - Cash Flow Conversion Efficiency Trend (2012–2025)

This chart illustrates how Tellgen Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Tellgen Corp Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Tellgen Corp ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Cotec Construction JSC
VN:CTD
-0.185x
DYNAGREEN EN.PR.GR.H YC 1
F:DYN
0.037x
Bleichroeder Acquisition Corp. II Class A Ordinary Shares
NASDAQ:BBCQ
-0.003x
Text S.A.
WAR:TXT
0.303x
Hutchison Telecommunications (Australia) Ltd
AU:HTA
0.783x
Giantplus Technology Co Ltd
TW:8105
0.004x
Zhubo Design
SHE:300564
-0.027x
Bintang Oto Global Tbk PT
JK:BOGA
0.031x

Annual Cash Flow Conversion Efficiency for Tellgen Corp (2012–2025)

The table below shows the annual cash flow conversion efficiency of Tellgen Corp from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see 300642 market cap overview.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 CN¥1.48 Billion
≈ $216.63 Million
CN¥143.23 Million
≈ $20.96 Million
0.097x -10.78%
2024-12-31 CN¥1.52 Billion
≈ $222.14 Million
CN¥164.62 Million
≈ $24.09 Million
0.108x +31.75%
2023-12-31 CN¥1.54 Billion
≈ $224.72 Million
CN¥126.40 Million
≈ $18.50 Million
0.082x -26.01%
2022-12-31 CN¥1.48 Billion
≈ $216.67 Million
CN¥164.72 Million
≈ $24.10 Million
0.111x +88.02%
2021-12-31 CN¥1.40 Billion
≈ $204.32 Million
CN¥82.61 Million
≈ $12.09 Million
0.059x -22.61%
2020-12-31 CN¥1.27 Billion
≈ $185.34 Million
CN¥96.83 Million
≈ $14.17 Million
0.076x -48.90%
2019-12-31 CN¥1.17 Billion
≈ $171.01 Million
CN¥174.84 Million
≈ $25.59 Million
0.150x -5.02%
2018-12-31 CN¥1.02 Billion
≈ $149.87 Million
CN¥161.32 Million
≈ $23.61 Million
0.158x +33.13%
2017-12-31 CN¥895.86 Million
≈ $131.09 Million
CN¥106.00 Million
≈ $15.51 Million
0.118x -65.30%
2016-12-31 CN¥288.65 Million
≈ $42.24 Million
CN¥98.42 Million
≈ $14.40 Million
0.341x +1.41%
2015-12-31 CN¥192.33 Million
≈ $28.14 Million
CN¥64.67 Million
≈ $9.46 Million
0.336x +7.97%
2014-12-31 CN¥131.05 Million
≈ $19.18 Million
CN¥40.81 Million
≈ $5.97 Million
0.311x +12.41%
2013-12-31 CN¥95.04 Million
≈ $13.91 Million
CN¥26.33 Million
≈ $3.85 Million
0.277x +193.02%
2012-12-31 CN¥72.47 Million
≈ $10.60 Million
CN¥6.85 Million
≈ $1.00 Million
0.095x --

About Tellgen Corp

SHE:300642 China Medical Devices
Market Cap
$297.79 Million
CN¥2.04 Billion CNY
Market Cap Rank
#14974 Global
#4439 in China
Share Price
CN¥12.52
Change (1 day)
-3.10%
52-Week Range
CN¥12.52 - CN¥31.30
All Time High
CN¥46.24
About

Tellgen Corporation researches and develops, manufactures, and distributes IVDs in China and internationally. The company offers tumor markers; cervical cancer and HPV testing kits; Y chromosome microdeletions test kits; autoimmune; tumor methylation; cardiovascular, eugenics, and inflammation. It also provides diagnostic reagents/testing instruments and assembly lines. The company was founded in… Read more